Trial Profile
A phase II study of efficacy and safety of Pegasys in patients with Chronic Phase Chronic Myeloid Leukaemia in PCR+ve complete or near complete cytogenetic remission on Glivec at 600 mg daily or maximum tolerated dose
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 12 May 2009 New trial record